Chemomab Therapeutics (CMMB) Receivables - Other (2017 - 2025)

Chemomab Therapeutics (CMMB) has 6 years of Receivables - Other data on file, last reported at $3.1 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Other rose 80.15% year-over-year to $3.1 million; the trailing twelve-month figure through Dec 2025 stood at $3.1 million (up 80.15% YoY), and the FY2025 full-year result was $3.1 million, up 80.15% from the prior year.
• Receivables - Other for Q4 2025 stood at $3.1 million, up from $1.7 million in the prior quarter.
• Across five years, Receivables - Other topped out at $3.1 million in Q4 2025 and bottomed at $439000.0 in Q3 2024.
• The 4-year median for Receivables - Other is $1.1 million (2023), against an average of $1.3 million.
• The widest annual swing landed in 2024, when Receivables - Other sank 52.39%; it then soared 292.03% in 2025.
• A 4-year view of Receivables - Other shows it stood at $1.8 million in 2022, then slumped by 41.28% to $1.0 million in 2023, then surged by 63.74% to $1.7 million in 2024, then jumped by 80.15% to $3.1 million in 2025.
• The last three Receivables - Other figures came in at $3.1 million (Q4 2025), $1.7 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.

Peer Comparison